To contribute towards the global effort to combat antibiotic resistance
Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections may otherwise be inadequately treated.
Cefepime/enmetazobactam has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled Phase 3 trial.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!